SDC2 and acute respiratory distress syndrome: ORBCELLTM (Orbsen Therapeutics, Ireland), which are CD362-enriched hUC-MSCs, are being used in the United Kingdom in a phase I/II trial of Acute Respiratory Distress Syndrome (REALIST35; and also in a phase II trial of autoimmune hepatitis, http://clinicaltrials.gov: NCT02585622).